Is CTKB or HBIO more undervalued in 2026?

CirclFi compares Cytek Biosciences, Inc. (CTKB) and Harvard Bioscience, Inc. (HBIO) using 13 institutional-grade valuation models. CTKB has a Quality of Company score of 6.8/10 while HBIO scores 5.7/10.

Which is a better buy — CTKB or HBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CTKB and HBIO valuations compare?

CTKB at $4.19 and HBIO at $5.88 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CTKB vs HBIO Valuation Comparison 2026 — Intrinsic Value Analysis

CTKB

Laboratory Analytical Instruments

Cytek Biosciences, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$4.19

Last close

Models

13/13

Active

HBIO

Laboratory Analytical Instruments

Harvard Bioscience, Inc.

Quality

5.7

out of 10

Value Trap

SAFE

Price

$5.88

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	CTKB Fair Value	CTKB Upside	HBIO Fair Value	HBIO Upside
Bayesian DCF	Intrinsic	$0.96	-77.0%	$10.78	+83.4%
Earnings Power Value	Intrinsic	$2.87	-37.8%	$14.18	+123.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTKB vs HBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTKB vs HBIO — Which Stock Is More Undervalued?

CTKB scores higher with a 6.8/10 quality rating vs HBIO's 5.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cytek Biosciences, Inc. (CTKB) and Harvard Bioscience, Inc. (HBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTKB currently trades at $4.19 with a QOC of 6.8/10, while HBIO trades at $5.88 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).